Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study

G Pezzoli1, E Martignoni, C Pacchetti

  • 1Institute of Clinical Neurology, University of Milan, Italy.

Movement Disorders : Official Journal of the Movement Disorder Society
|July 1, 1994
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Etiology, presentation and management of urinary tract infections in multiple sclerosis patients: A review of the current literature.

Urologia·2024
Same author

Dynamic evaluation of spine kinematics in individuals with Parkinson's disease and freezing of gait.

Gait & posture·2023
Same author

Correction to: Gender differences in microRNA expression in levodopa‑naive PD patients.

Journal of neurology·2023
Same author

Gender differences in microRNA expression in levodopa-naive PD patients.

Journal of neurology·2023
Same author

Radical Nephroureterectomy Tetrafecta: A Proposal Reporting Surgical Strategy Quality at Surgery.

European urology open science·2022
Same author

The impact of COVID-19 outbreak on urolithiasis emergency department admissions, hospitalizations and clinical management in central Italy: a multicentric analysis.

Actas urologicas espanolas·2020

Pergolide demonstrated superior efficacy compared to bromocriptine as an add-on therapy for Parkinson's disease (PD) patients experiencing reduced levodopa effectiveness. Patients and clinicians favored pergolide, with fewer adverse events observed.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease (PD) management often requires adjunctive therapies when levodopa response declines.
  • Dopamine agonists like pergolide and bromocriptine are used to manage motor fluctuations.

Purpose of the Study:

  • To compare the efficacy and safety of pergolide versus bromocriptine in patients with Parkinson's disease (PD) experiencing a diminished response to levodopa.
  • To evaluate patient and clinician preference between pergolide and bromocriptine.

Main Methods:

  • A single-blind, crossover study involving 57 Parkinson's disease patients.
  • Patients received either bromocriptine then pergolide, or vice versa, for 12 weeks each.
  • Evaluations included the New York University Parkinson's Disease Scale, clinician assessments, and patient/clinician impressions.

Related Experiment Videos

Main Results:

  • Both pergolide and bromocriptine significantly improved outcomes compared to levodopa alone.
  • Pergolide showed greater efficacy than bromocriptine in improving daily living and motor scores (p=0.020 and p=0.038, respectively).
  • Adverse events were more frequent with bromocriptine; no significant differences in dyskinesias, dystonias, or psychosis were noted.

Conclusions:

  • Pergolide is a more effective adjunctive therapy than bromocriptine for Parkinson's disease patients with declining levodopa response.
  • Pergolide was associated with a better tolerability profile and higher patient/clinician preference in this trial.